TP53 and cancer: Compared to drug‐sensitive SW48‐Dox cells, GCS activities were seen to be significantly higher in drug‐resistant cancer cells, by approximately twofold (96 vs 51 fmol/μg, P < .001) in TP53‐Dox, and by sevenfold (132 vs 18 fmol/μg, P < .001) in WiDr cells (Figure 2B, left).